112 related articles for article (PubMed ID: 37247937)
1. The Suppressive Effect of Rebastinib on Triple-negative Breast Cancer Tumors Involves Multiple Mechanisms of Action.
Feng K; Jian C; Xiao H; Jiang H; Yang J; Yang M; Sun A; Song W; Chestkov AV; Vasilevich NI; Sun L
Anticancer Res; 2023 Jun; 43(6):2609-2624. PubMed ID: 37247937
[TBL] [Abstract][Full Text] [Related]
2. CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1.
Li X; Li J; Xu L; Wei W; Cheng A; Zhang L; Zhang M; Wu G; Cai C
J Exp Clin Cancer Res; 2022 Apr; 41(1):149. PubMed ID: 35449080
[TBL] [Abstract][Full Text] [Related]
3. The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2
Harney AS; Karagiannis GS; Pignatelli J; Smith BD; Kadioglu E; Wise SC; Hood MM; Kaufman MD; Leary CB; Lu WP; Al-Ani G; Chen X; Entenberg D; Oktay MH; Wang Y; Chun L; De Palma M; Jones JG; Flynn DL; Condeelis JS
Mol Cancer Ther; 2017 Nov; 16(11):2486-2501. PubMed ID: 28838996
[TBL] [Abstract][Full Text] [Related]
4. Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negative xenograft growth.
Chai Y; Lee HJ; Shaik AA; Nkhata K; Xing C; Zhang J; Jeong SJ; Kim SH; Lu J
Breast Cancer Res; 2010; 12(5):R67. PubMed ID: 20809980
[TBL] [Abstract][Full Text] [Related]
5. Ginsenoside Rk1 induces cell cycle arrest and apoptosis in MDA-MB-231 triple negative breast cancer cells.
Hong Y; Fan D
Toxicology; 2019 Apr; 418():22-31. PubMed ID: 30797898
[TBL] [Abstract][Full Text] [Related]
6. Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling.
Ji X; Meng X; He Q; Xiang X; Shi Y; Zhu X
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614199
[TBL] [Abstract][Full Text] [Related]
7. Chloroform Fraction of Methanolic Extract of Seeds of Annona muricata Induce S Phase Arrest and ROS Dependent Caspase Activated Mitochondria-Mediated Apoptosis in Triple-Negative Breast Cancer.
Kariyil BJ; Ayyappan UPT; Gopalakrishnan A; George AJ
Anticancer Agents Med Chem; 2021; 21(10):1250-1265. PubMed ID: 32951586
[TBL] [Abstract][Full Text] [Related]
8. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
9. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis.
Kim S; Min A; Lee KH; Yang Y; Kim TY; Lim JM; Park SJ; Nam HJ; Kim JE; Song SH; Han SW; Oh DY; Kim JH; Kim TY; Hangauer D; Lau JY; Im K; Lee DS; Bang YJ; Im SA
Cancer Res Treat; 2017 Jul; 49(3):643-655. PubMed ID: 27737538
[TBL] [Abstract][Full Text] [Related]
11. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
12. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
13. Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.
Messeha SS; Zarmouh NO; Asiri A; Soliman KFA
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33297339
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
15. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
Diamond JR; Eckhardt SG; Tan AC; Newton TP; Selby HM; Brunkow KL; Kachaeva MI; Varella-Garcia M; Pitts TM; Bray MR; Fletcher GC; Tentler JJ
Clin Cancer Res; 2013 Jan; 19(1):291-303. PubMed ID: 23136197
[TBL] [Abstract][Full Text] [Related]
16. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
Salem I; Alsalahi M; Chervoneva I; Aburto LD; Addya S; Ott GR; Ruggeri BA; Cristofanilli M; Fernandez SV
Breast Cancer Res; 2016 Mar; 18(1):37. PubMed ID: 27009091
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
[TBL] [Abstract][Full Text] [Related]
18. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
19. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
20. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]